ARCHIVES

FDA Didn’t Punish Duke for Failing To Seek Proper Regulatory Clearance for Three Trials

This article is from The Cancer Letter archive.

Vol. 38 No. 04 | January 27, 2012

Download PDF Visit The Full Archive

Related Articles

Early HER2 Positive Patients At Higher Risk of Recurrence

January 30, 2009

NIH Panel Calls for Further Research On End-of-Life Issues.

January 21, 2005

SEC Notifies ImClone It May Bring Action Against Company

June 21, 2002

Only 45 CCOPs Likely To Be Funded Unless More Money Is Made Available; ACCC Goes To Congress

March 20, 1987

Preoperative Drug Combo Benefits HER-2 Breast Cancer

April 29, 2005

“NCI activities at Frederick are not well integrated…. It would be wise to reorganize and consolidate.”

July 21, 1995